IonQ Vice President and GM of Quantum Platform Matthew Keesan joins BioTalk for a clear look at how they are advancing quantum computing from its home base in the BioHealth Capital Region. He shares the story of IonQ’s Maryland roots and explains quantum computing in straightforward terms for listeners seeking a high-level understanding. The conversation moves into why biohealth leaders should track the hardware race, what distinguishes IonQ’s approach, and how quantum is already being paired with AI to strengthen modeling and analysis. Keesan walks through early use cases showing traction today, challenges common myths about timelines, and shares which biohealth applications he expects to gain mainstream momentum by 2030.
Listen via your favorite Podcast Platform:
Apple: https://apple.co/4qfo8ON
Spotify: https://bit.ly/3KXjINr
iHeart Podcasts: https://ihr.fm/4q3DaH8
Amazon Music Podcasts: https://amzn.to/3MBCaM2
YouTube Music Podcasts: https://bit.ly/4qab0uf
TuneIn: https://bit.ly/3MECNEA
Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).
Matthew Keesan is Vice President and GM of Quantum Platform at IonQ and a member of the BHI Board. He joined IonQ in 2017 to lead the development of the company’s Quantum OS, the software stack that controls IonQ’s quantum computers. In 2021, he oversaw the launch of IonQ’s Harmony systems on Amazon Braket, Microsoft Azure Quantum, and Google Cloud, making IonQ the first quantum hardware provider available across all three hyperscalers. He built IonQ’s security function to meet commercial and government frameworks, including SOC 2, NIST 800-171, NIST 800-53, and ISO 27001, and established a globally distributed operations team managing IonQ’s fleet of quantum computers across the United States and Europe.
Before joining IonQ, Keesan served as CTO of the restaurant technology company Ando, which was acquired by Uber, and advised startups in manufacturing, e-commerce, and identity-as-a-service. He also helped create the technology behind the interactive HBO series Mosaic with Steven Soderbergh. He holds patents in quantum compilation, hybrid quantum computation, and quantum control automation, and has co-authored papers published in Nature and Physical Review A.
William Hurley, known widely as Whurley, joins BioTalk for a deep look at how quantum computing is moving from theory into practical use across the biohealth landscape. He opens the conversation with an introduction to Strangeworks and explains why the company is focused on making quantum computing more accessible for real-world problem-solving. The discussion explores how quantum could support breakthroughs in genomics and personalized medicine, improve the way clinical trials are modeled, and strengthen manufacturing and supply chain operations. Whurley also talks through the ingredients required for regional leadership in this space, including infrastructure, strategic partnerships, and a specialized workforce. He shares his view on what will distinguish successful players in quantum from those who overpromise or misread the market, and closes with a forward look at the convergence of quantum, AI, and biotechnology and the impact these capabilities could have on healthcare innovation. The conversation follows his recent keynote appearance at the BioHealth Capital Region Forum this past September.
Secretary Juan Pablo Segura joins BioTalk for a conversation about Virginia’s growing position in the biohealth economy and the statewide strategy behind it. He outlines the significance of the new partnership with AstraZeneca, Lilly, and Merck, including up to $120 million in private investment to create a workforce development center and expand the Commonwealth’s life sciences capacity. Segura talks through how Virginia approaches company recruitment, what investors are responding to, and why the state is seeing increased interest from biomanufacturing and advanced R&D companies. He also discusses Virginia’s use of public-private partnerships to accelerate industry growth, strengthen the talent pipeline, and support emerging hubs across the Commonwealth. The conversation closes with a look at Virginia’s role in the BioHealth Capital Region and how the regional identity helps amplify the state’s message as it continues building a competitive biohealth ecosystem.
This episode brings together three leaders working at the intersection of pediatric innovation, health security, and early-stage commercialization. Kolaleh Eskandanian, Program Director of SPARK, is joined by founders Dori Jones of AcQumen Medical and Jugal Suthar of Vesynta for a conversation about advancing breakthrough solutions for children. They discuss the mission behind the BARDA-funded SPARK for Innovations in Pediatrics Hub at Children’s National Hospital, the challenges of developing technologies for pediatric populations, and the impact of public-private partnerships in moving lifesaving tools to market. Dori and Jugal share what their companies are building, the inflection points that shaped their journeys, and how BioHealth Innovation’s Entrepreneur-in-Residence program supported their progress. The group reflects on lessons learned, the value of mentorship, and how collaborative accelerator ecosystems help drive breakthroughs in pediatric care, preparedness, and health equity.
Getting a biotech company off the ground takes more than science; it takes strategy, funding, and the right network. 
In this episode of BioTalk, Rich Bendis welcomes Dr. Helen Sabzevari, President and CEO of Precigen, to discuss the company’s cutting-edge science in gene and cell therapy. Dr. Sabzevari shares how Precigen’s unique AdenoVerse® platform has powered the development of PRGN-2012, a potential first-in-class therapeutic currently under FDA priority review for the treatment of adults with recurrent respiratory papillomatosis (RRP), a rare and devastating disease. She also highlights advances across Precigen’s broader pipeline in immuno-oncology and autoimmune disease and reflects on how Maryland’s BioHealth Capital Region has supported the company’s innovation and growth.
